Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

[Image: see text] The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in millions of deaths and threatens public health and safety. Despite the rapid global spread of COVID-19 vaccines, effective oral antiviral drugs...

Descripción completa

Detalles Bibliográficos
Autores principales: Unoh, Yuto, Uehara, Shota, Nakahara, Kenji, Nobori, Haruaki, Yamatsu, Yukiko, Yamamoto, Shiho, Maruyama, Yuki, Taoda, Yoshiyuki, Kasamatsu, Koji, Suto, Takahiro, Kouki, Kensuke, Nakahashi, Atsufumi, Kawashima, Sho, Sanaki, Takao, Toba, Shinsuke, Uemura, Kentaro, Mizutare, Tohru, Ando, Shigeru, Sasaki, Michihito, Orba, Yasuko, Sawa, Hirofumi, Sato, Akihiko, Sato, Takafumi, Kato, Teruhisa, Tachibana, Yuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982737/
https://www.ncbi.nlm.nih.gov/pubmed/35352927
http://dx.doi.org/10.1021/acs.jmedchem.2c00117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982737/
https://www.ncbi.nlm.nih.gov/pubmed/35352927
http://dx.doi.org/10.1021/acs.jmedchem.2c00117

Ejemplares similares